Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy
- 1 August 1999
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 56 (2) , 714-719
- https://doi.org/10.1046/j.1523-1755.1999.00597.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Transforming growth factor-β1 hyperexpression in African American end-stage renal disease patientsKidney International, 1998
- Interactions of Transforming Growth Factor-β and Angiotensin II in Renal FibrosisHypertension, 1998
- Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathyKidney International, 1997
- IN VIVO HYPEREXPRESSION OF TRANSFORMING GROWTH FACTOR-??1 IN MICE: STIMULATION BY CYCLOSPORINE1Transplantation, 1997
- Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cellsKidney International, 1997
- Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejectionKidney International, 1996
- Altered expression of transforming growth factor-βs in chronic renal rejectionKidney International, 1996
- Transforming Growth Factor β in Tissue FibrosisNew England Journal of Medicine, 1994
- Chronic rejection.Journal of the American Society of Nephrology, 1994
- International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathologyKidney International, 1993